The FDA has approved Widaplik (telmisartan, amlodipine and indapamide) for the treatment of hypertension, including as initial treatment, to lower blood pressure.

The FDA has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.

The FDA has approved Widaplik, a polypill combining telmisartan, amlodipine, and indapamide, for the treatment of ...

The FDA approved a polypill containing telmisartan, amlodipine, and indapamide, known as Widaplik, for the treatment of ...

The FDA has approved a new pill called Widaplik, which combines three drugs – telmisartan, amlodipine, and indapamide – to treat adults who have high blood pressure.

The FDA has approved Widaplik, a triple-drug combination, for the treatment of hypertension in adults.

Widaplik marks the first and only FDA-approved triple combination medication that can be used as an initial therapy for patients with hypertension who require multiple drugs to reach their blood ...

A new era of hypertension treatment is on the horizon for U.S. | The drug is the first triple-combo pill for the initial ...

WIDAPLIK is a proprietary single pill combination of three medicines: telmisartan, amlodipine and indapamide and is available in three doses: a standard dose and two low doses. It is the first and ...

Widaplik is a single tablet, triple combination therapy for hypertension that is expected to be available in the fourth quarter of 2025. The Food and Drug Administration (FDA) has approved ...

The FDA approval is based on positive results from two international phase 3 trials that compared Widaplik to dual combinations of its component drugs as well as to placebo. The results of both ...

WEDNESDAY, June 11, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.